SP-131-1
We have developed multiple drug candidates modeled after mitragynine pseudoindoxyl, a compound derived from the kratom leaf. These analogues are designed to deliver pain relief while minimizing the risk of addiction, addressing a key issue associated with opioid-based therapies.

SP-141-2
We are developing several drug candidates inspired by compounds found in the Kanna plant, known for their potential to alleviate symptoms of major depressive disorder. These compounds aim to offer effective treatment with fewer side effects compared to traditional antidepressants.

SP-151-3
Derived from alkaloids in the Corydalis plant, these drug candidates target neuropathic pain pathways, providing relief for conditions like fibromyalgia and diabetic neuropathy while minimizing dependency risks.

SP-161-4
Inspired by salvinorin A from Salvia divinorum, these compounds selectively modulate kappa-opioid receptors, offering a potential treatment for severe mood disorders and anxiety without the dissociative effects of the original compound.

SP-171-5
Modeled after betulinic acid from birch bark, these compounds target aggressive cancers like melanoma and glioblastoma, leveraging apoptosis-inducing mechanisms to destroy cancer cells while sparing healthy tissue.

SP-181-6
Derived from withaferin A in ashwagandha, these candidates are being developed for their immunomodulatory and anti-inflammatory properties, offering potential therapies for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis.

SP-191-7
Inspired by psilocybin from fungi, these analogues aim to treat treatment-resistant depression and PTSD. They are being engineered to retain therapeutic benefits while reducing hallucinogenic effects for greater accessibility.

SP-201-8
Based on capsaicin from chili peppers, these compounds target pain receptors to provide long-lasting relief for conditions like arthritis, while avoiding systemic side effects commonly associated with pain management drugs.

SP-211-9
Modeled after baicalin from Scutellaria baicalensis (Chinese skullcap), these drug candidates focus on neuroprotective and anti-inflammatory effects, aiming to slow the progression of Alzheimer’s and Parkinson’s diseases.

SP-221-10
Inspired by artemisinin from the sweet wormwood plant, these analogues are optimized to overcome drug resistance in malaria treatment, offering a new solution to a critical global health challenge.